Browse hierarchy: [Obstetrics/Gynecology (OB)](/submissions/OB) → [Subpart G — Assisted Reproduction Devices](/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices) → [21 CFR 884.6195](/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/884.6195) → PBH — Embryo Image Assessment System, Assisted Reproduction

# PBH · Embryo Image Assessment System, Assisted Reproduction

_Obstetrics/Gynecology · 21 CFR 884.6195 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/PBH

## Overview

- **Product Code:** PBH
- **Device Name:** Embryo Image Assessment System, Assisted Reproduction
- **Regulation:** [21 CFR 884.6195](/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/884.6195)
- **Device Class:** 2
- **Review Panel:** [Obstetrics/Gynecology](/submissions/OB)

## Identification

An Assisted Reproduction Embryo Image Assessment System is a prescription device that is designed to obtain and analyze light microscopy images of developing embryos. This device provides information to aid in the selection of embryo(s) for transfer when there are multiple embryos deemed suitable for transfer or freezing.

## Classification Rationale

Class II (special controls). The special control(s) for this device are:

## Special Controls

In combination with the general controls of the Food, Drug &Cosmetic Act, Assisted Reproduction Embryo Image Assessment Systems are subject to the following special controls:

*Classification.* Class II (special controls). The special control(s) for this device are:(1) Clinical performance testing must demonstrate a reasonable assurance of safety and effectiveness of the device to predict embryo development. Classification performance (sensitivity and specificity) and predictive accuracy (Positive Predictive Value and Negative Predictive Value) must be assessed at the subject and embryo levels.
(2) Software validation, verification, and hazard analysis must be provided.
(3) Non-clinical performance testing data must demonstrate the performance characteristics of the device. Testing must include the following:
(i) Total light exposure and output testing;
(ii) A safety analysis must be performed based on maximum (worst-case) light exposure to embryos, which also includes the safety of the light wavelength(s) emitted by the device;
(iii) Simulated-use testing;
(iv) Mouse Embryo Assay testing to assess whether device operation impacts growth and development of mouse embryos to the blastocyst stage;
(v) Cleaning and disinfection validation of reusable components;
(vi) Package integrity and transit testing;
(vii) Hardware fail-safe validation;
(viii) Electrical equipment safety and electromagnetic compatibility testing; and
(ix) Prediction algorithm reproducibility.
(4) Labeling must include the following:
(i) A detailed summary of clinical performance testing, including any adverse events;
(ii) Specific instructions, warnings, precautions, and training needed for safe use of the device
(iii) Appropriate electromagnetic compatibility information;
(iv) Validated methods and instructions for cleaning and disinfection of reusable components; and
(v) Information identifying compatible cultureware and explain how they are used with the device.

## Recent Cleared Devices (4 of 4)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K243851](https://fda.innolitics.com/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/PBH/K243851.md) | CHLOE BLAST | Fairtility , Ltd. | Aug 15, 2025 | SESE |
| [K182798](https://fda.innolitics.com/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/PBH/K182798.md) | KIDScore D3 | Vitrolife A/S | Jul 19, 2019 | SESE |
| [K142147](https://fda.innolitics.com/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/PBH/K142147.md) | EEVA SYSTEM | Auxogyn, Inc. | Nov 24, 2014 | SESE |
| [DEN120015](https://fda.innolitics.com/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/PBH/DEN120015.md) | EEVA 2.0 | Auxogyn, Inc. | Jun 6, 2014 | DENG |

## Top Applicants

- Auxogyn, Inc. — 2 clearances
- Fairtility , Ltd. — 1 clearance
- Vitrolife A/S — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/PBH](https://fda.innolitics.com/submissions/OB/subpart-g%E2%80%94assisted-reproduction-devices/PBH)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com